NCT06380738 Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
| NCT ID | NCT06380738 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Metastatic Castration-resistant Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2024-02-14 |
| Primary Completion | 2027-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2024-02-14 with a primary completion date of 2027-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PROceed is a multisite, prospective, observational study that describes the real-world use and clinical experience of mCRPC patients treated with the combination of olaparib and abiraterone in the mCRPC setting. Clinical outcomes will be assessed in patients who are either NHA-naive or NHA-exposed prior to initiating olaparib + abiraterone treatment, respectively. Patient demographic and clinical characteristics, as well as treatment received prior and subsequent to olaparib + abiraterone, will also be described. The study plans to enroll patients for a maximum of 2 years and follow up patients from initiation of olaparib until 1 year post last patient in.
Eligibility Criteria
Inclusion Criteria: * Willing and able to provide written informed consent; * 18 years of age and above; * Documented histopathology or cytopathology of PCa, adenocarcinoma; * Confirmed as mCRPC; * Initiated olaparib + abiraterone after site activation Exclusion Criteria: * Patients participating in a clinical trial with an investigational prostate cancer treatment within 30 days prior to olaparib initiation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06380738 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Castration-resistant Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06380738 currently recruiting?
Yes, NCT06380738 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT06380738 trial being conducted?
This trial is being conducted at Aschaffenburg, Germany, Augsburg, Germany, Bergisch Gladbach, Germany, Berlin, Germany and 11 additional locations.
Who is sponsoring the NCT06380738 clinical trial?
NCT06380738 is sponsored by AstraZeneca. The trial plans to enroll 250 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.